



Pharmacy Formulary Updates for July 2019

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status July 2019:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Together MCO- MA
Lenvima	\$3.65;PA;SP
Erleada	NC;SP
Yonsa	NC;SP
Flunisolide nasal	\$3.65;PA
Jivi	MB/RX;PA;SP
Omeprazole/sodium bicarbonate cap/packet	\$3.65;PA;QL
Elzonris	MB/RX
Firdapse	\$3.65;PA
Xepi	\$3.65;PA;QL
Krintafel	\$3.65;QL
Arakoda	NC
Prograf granules	\$3.65
Herceptin-Hylecta	MB/RX
Tironsit-Sol	NC
Lotemax SM	\$3.65;PA
Dsuvia	MB
Guanidine	\$3.65
Methyldopa/HCTZ	\$1
Zykadia 150mg	\$3.65;PA;SP
Lokelma	\$3.65
Oxervate	\$3.65;PA
Seysara	NC
Yupelri	NC
Bijuva	NC

Zinbryta	\$3.65;QL
Methadone Oral Concentrate	MB
Sirolimus Oral Solution	\$3.65

Key

MB: Medical Benefit **QL:** Quantity Limitation
NC: Not covered **SP:** Specialty Pharmacy - provided
NTM: New-to-market through CVS/specialty
PA: Prior Authorization **ST:** Step Therapy
MB/RX: Drug can be dispensed through Medical Benefit or Prescription Benefit